Arrowhead Pharmaceuticals (NASDAQ: ARWR) stock has climbed over 45% higher after the company announced positive interim results from its Phase 2 study of ARO-AAT in treating a rare genetic liver disease.
Arrowhead said that the therapeutic, which is being used in the study to treat a rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD), showed clear evidence of a meaningful effect leading to improvements in patients.
“The improvements in additional clinically meaningful biomarkers, including reductions in Z-AAT polymer, improvements in FibroScan values, and decreases in ALT and GGT, were more substantial than we expected,” said Javier San Martin, MD, chief medical officer at Arrowhead.
Sponsored content
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Arrowhead shares…
Arrowhead ($ARWR)/Source: TradingView
The news resulted in a leap in Arrowhead’s share price. It closed Wednesday’s trading session at $33.80 and is currently trading at $49.22 per share, up over 45%.
Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples.
